Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALDX
#3980
Aldeyra Therapeutics, Inc. - Common Stock
1.4
9
USD
-0.03%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-3.25%
Monthly Change
-5.70%
6 month change
-72.41%
Year Change
-74.57%
Previous Close
1.5
4
Open
1.5
0
Low
1.4
8
High
1.5
1
Volume
155
Markets
US Stock Market
Healthcare
Biotechnology
ALDX
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
47.25 M
58.1 M
58.58 M
58.9 M
59.71 M
60.18 M
60.33 M
Valuation ratios
Enterprise value
261.35 M
18.11 M
279.11 M
79.22 M
258.45 M
241.71 M
91.7 M
Price to earnings ratio
—
—
-6.57
-5.53
-5.31
-9.25
-4
Price to sales ratio
—
—
—
—
—
-1 164
—
Price to cash flow ratio
—
—
-7.18
-6.88
-6.87
-9.33
-4.16
Price to book ratio
—
—
2.69
1.74
4.18
7.03
0.53
Enterprise value to EBITDA ratio
—
—
—
—
—
-22.35
-11.01
Profitability ratios
Return on assets %
-0.45
-0.25
-0.34
-0.25
-0.53
-0.47
-0.11
Return on equity %
-0.63
-0.28
-0.41
-0.31
-0.79
-0.76
-0.14
Return on invested capital %
-1 273.14
-9 369.38
-24.54 K
-239.61
-324.33
-646.89
—
Gross margin %
—
—
—
—
—
100
—
Operating margin %
—
—
—
—
—
13.2 K
—
EBITDA margin %
—
—
—
—
—
4 047.04
—
Net margin %
—
—
—
—
—
12.66 K
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.69
19.77
11.78
6.64
5.59
2.58
4.91
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
-0
0
Solvency ratios
Debt to assets ratio
0.14
0.07
0.08
0
0.14
0
—
Debt to equity ratio
0.19
0.08
0.1
0
0.21
0
—
Long term debt to total assets ratio
0.19
0.07
0.09
0.1
0.15
0.21
—
Long term debt to total equity ratio
0.27
0.08
0.11
0.13
0.22
0.35
—
Per share metrics
Operating cash flow per share
—
—
-0.97
-0.51
-0.73
-0.56
-0.37
EBIT per share
—
—
—
—
—
-0.17
-0.14
EBITDA per share
—
—
—
—
—
-0.18
-0.14
Total debt per share
—
—
0.27
0.26
0.25
0
—
Cash per share
—
—
3.5
0
2.48
1.17
—
Net current asset value per share
—
—
3.1
2.51
1.75
1.2
0.79
Tangible book value per share
—
—
2.59
2.03
1.19
0.74
0.63
Working capital per share
—
—
2.84
2.13
1.44
0.73
0.63
Book value per share
—
—
2.59
2.03
1.19
0.74
0.63
News
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX)
Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims - TipRanks.com
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV)
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.10%
RBC reiterates Bausch & Lomb stock rating on DED rival delay
FDA rejects Aldeyra’s dry eye disease drug application
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
Top Healthcare Stocks for This Year According to BTIG